Ariana Boswell

All articles by Ariana Boswell

• People with type 2 diabetes at greater risk of endometrial cancer

  A combination of hormonal, metabolic and inflammatory mechanisms may contribute to the relationship between T2DM and EC.

• Sugar-sweetened beverages may increase endometrial cancer risk

  A large-scale analysis of data from the UK Biobank demonstrated that sugar-sweetened beverages may raise the risk of endometrial cancer (EC).

• Older patients with endometrial cancer less likely to choose chemotherapy

  Though older individuals with EC are less likely overall to desire chemotherapy, there is wide variation in opinions, a study found.

• Obesity linked to poorer response to pembrolizumab in endometrial cancer

  A study found that progression-free survival, but not overall survival, was worse among obese patients with EC treated with pembrolizumab.

• Review: Metabolic changes may signal risk of endometrial cancer

  Although EC is strongly linked with obesity, other factors including metabolic instability should also be considered, a recent study found.

• What you should know about immunotherapy for endometrial cancer

  Immunotherapy overrides the cancer cells’ defenses, allowing your immune system to attack the EC cells.

• Tips for staying hydrated during endometrial cancer treatment

  Learn how to increase your fluid intake and maintain your electrolyte balance during endometrial cancer treatment.

• Study suggests link between dairy consumption and endometrial cancer risk

  Researchers asked patients with EC and controls about their eating habits, finding that cases had lower average dairy consumption.

• Reduced lenvatinib dose for EC improves safety but lowers efficacy

  Lower lenvatinib doses are often used to prevent side effects in patients with advanced EC, but this could lead to worse survival outcomes.

• Potential EC therapy receives Breakthrough Therapy Designation from FDA

  Rina-S is a novel therapy designed for patients with endometrial cancer who do not respond to platinum-based therapies of PD-L1 immunotherapy.